H.C. Wainwright lowered the firm’s price target on Context Therapeutics (CNTX) to $4 from $5 and keeps a Buy rating on the shares following the Q2 report.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX: